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Reduction in tl2-Receptor Autoantibody Level in
Patients with Idiopathic Dilated Cardiomyopathy
During Mechanical Cardiac Assist System
Support
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Conclusion: Mechanical cardiac assist device support not only leads to
an improvement in the hemodynamic condition of pts, but apparently also
In immunological changes, such as a diminished presentation of specific
antigens and a consecutive reduction of autoantibodies, which in the future
may be important in assessing the indication for weaning from cardiac assist
devices instead of performing transplantation.
Johannes Muller, Gerd Wallukat 1, Henryk Siniawski, Yougo Weng, Roland Hetzer.
German Heart Institute, Berlin, Germany; 1 Max De/brOck Center- Berlin, Germany
Ten patients (pts) with idiopathic dilated cardiomyopathy were implanted
with mechanical left ventricular assist devices (Novacor, TCI) as a bridge to
transplantation. The following pre-implantation data was observed: right and
left ventricular ejection fraction <20%, x-ray heart-lung ratio >0.68, left ven-
tricular diameter>7.9 em, and central venous pressure >25 mmHg. All pts
were in NYHA class IV and at least on a medium dose of catecholamines.
tJrreceptor autoantibody (RAAB) levels were measured by bioassay before
implantation and once a week postoperatively. All pts clinically recovered
within 6-8 weeks, RAABs were not detected in two pts while in eight pts
who preoperatively exhibited a relative level of 25 ± 8 the level decreased
during the ensuing 14 weeks to zero in 6 pts. These 6 pts were supported
with a device which operated synchronously with the patient's heart rate
thus leading to optimal reduction in the afterload of the left ventricle (Fig.l.
The RAAB level decreased more gradually in the other 2 pts reaching zero
three weeks later. A non-synchronized device which did not provide the same
degree of afterload reduction was implanted in these pts (Fig.1. Although they
exhibited a reduction in RAABs and heart rate, a significant improvement in
cardiac function, and a decrease in heart size, the two pts with no detectable
RAABs exhibited neither an improvement in c2rdiac function nor a reduction
in cardiac diameter.
ABSTRACTS 23A
ditivity, and less than unity when suggesting antagonism. The synergy index
was 0.66 (95% confidence interval 0.46 to 0.94) for mortality at the end of
the study, and 0.68 (0.44 to 1.04) for 30-day mortality, indicating antagonism
between enalapril and ASA. No significant interaction was found regarding
nonfatal major events.
Conclusion: We found evidence of enalapril-ASA interaction. Excess mor-
talityoccurred when enalapril was randomized to patients using ASA at base-
line.
Before LVAD 1wk post 8 wks post Normals
MAP 65 ± 4 93 ± 6* 92 ± 5* 89 ± 9
Peak FBF 5.9 ± 16 95 ± 4.8 16.4 ± 2.8* 31.5 ± 2.71
Conductance 010 ± 0.03 0.10 ± 0.05 0.18 ± 0.03* 0.36 ± 0.05f
EDV(cc) EF(%) COIUmin) RFI%)
PreOp 317 ± 111 18 ± 5 3.1 ± 1.0 70 ± 12
PestOp 291 ± 106 24 ± 9 4.6 ± 0.8 13 ± 10
A -26 ± 31 +6 ± 5 +15 ± 0.9 -57 ± 15
P 0.04 0.02 0004 <0.001
* indicates p < 0.05 vs. Before LVAD, 1 indicates p < 005 vs. 8 wks post-LVAD
Mean CO increased from 2.3 IImin before LVAD to 5.4 l/min 1 and 8 wks
during LVAD support. Despite early normalization of CO and MAP within 1
week after LVAD, the maximum vascular conductance after brachial artery
occlusion did not change after 1week, and remained less than that observed
in normal subjects after 8 weeks of LVAD support. The delayed and incom-
plete reversal of abnormal metabolic vasodilation during long-term contin-
uous LVAD support suggests that mechanisms in addition to reduced CO
contribute to decreased metabolic vasodilation in patients with CHE
Mitral regurgitation (MR) frequently complicates cardiomyopathy (CM) and
contributes to symptoms of congestive heart failure (CHF). This study was
undertaken to assess the changes in CHF and left ventricular (LVI systolic
performance following mitral valve reconstruction (MVR) in patients with se-
vere MR secondary to end-stage dilated CM. Nine consecutive patients (age
64 ± 10 yrs) with severe LV dysfunction (ejection fraction [EFI 18 ± 5% [10-
25%]). severe MR and NYHA Class III (n = 1) or IV (n = 8) CHF despite ag-
gressive medical therapy undervvent MVR. All patients were receiving ther-
apy including digoxin, diuretics and afterload reducers. Two patients were
awaiting heart transplantation.
There were no operative deaths or deaths on 17 ± 5 (8-24) week follow-
up (PostOp). All patients noted symptomatic improvement NYHA Class im-
proved from 3.9 ± 0.3 pre-operatively (PreOp) to 1.7 ± 0.5 (p < 0.001) Di-
uretic requirements were markedly lower for 5 of 9 patients and stable for
the remaining 4. Ouantitative 2D echo/Dopplerwas performed on all patients
PreOp and on 8 of 9 patients PostOp. MR was absent or mild on follow-up in
all. Matched PreOp and PostOp LV end-diastolic volume (EDVL EF. forward
cardiac output (CO) and regurgitant fraction (RF) were compared for change
(6.):
Improvement in CHF occurred after MVR in all patients on short-term
follow-up, accompanied by lower LV end-diastolic volume and increased EF
and forvvard cardiac output Mitral reconstruction may be a new strategy for
the treatment of patients with severe MR complicating end-stage cardiomy-
opathy.
pressure (MAP, mmHg) was measured during each FBF measurement in the
contralateral arm by cuff method. MAP, peak FBF. and maximum vascular
conductance (calculated in arbitrary units as FBF/MAP) after arterial occlu-
sion were as follows:
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Early Improvement in Congestive Heart Failure
Following Correction of Secondary Mitral
Regurgitation in End-Stage Cardiomyopathy
David S. Bach, William F. Armstrong, Steven F. Bolling. University of Michigan, Ann
Arbor, MI
Lloyd A. Marks, Anthony J. Groch. Temple University Department of Pediatrics, St.
Christopher's Hospital for Children, Philadelphia, PA
Hypovolemic shock is difficult to recognize in its early stages because clin-
ically significant changes in heart rate (HRl. blood pressure (BPl. and urine
output occur late in its course. This study was conducted to determine if
changes in peripheral pulse volume (PV) occur early in acute blood loss, prior
to clinically significant changes in HR or BP PV is defined as the maximum
change in volume of a limb segment (e.g. calf) occuring during the cardiac
cycle and is measured noninvasively with a digitally enhanced admittance
plethysmograph. HR, systolic BP (SBP), diastolic BP (DBP), and calf PV (in
microliters, JlL) were measured in 35 male blood donors (age = 38.7 ± 11.1
[sd] yrs, weight = 87.7 ± 15.3 [sd] kg) before and after donating a unit of
whole blood (the average blood loss was 5.3 ± 0.9 [sd] mllkg). Pre and post
donation measurements were compared using paired Student's t-test. The
results (mean ± se) are tabulated below and illustrated above:
Antagonism Between Enalapril and Aspirin:
Subgroup Analysis of the Cooperative New
Scandinavian Enalapril Survival Study II
(CONSENSUS II)
Khang N. Nguyen, Ivar Aursnes, Steve Snapinn, John Kjekshus. University of Oslo
and National Hospital, Oslo, Norway
Several drugs have been investigated regarding their effect on mortality
when given early after an acute myocardial infarction. The use of angiotensin-
converting enzyme (ACE) inhibitors has been studied in several trials with in-
consistent results. Aspirin (ASA) has become a well documented therapeutic
adjunct in patients with coronary heart disease. Attention has recently been
focused on a possible interaction between aspirin and ACE inhibitors. We
therefore reanalyzed data from the CONSENSUS II to find any evidence of
differential effects of the ACE inhibitor enalapril in subgroups defined by use
of ASA at baseline.
Stepwise logistic regression tested the multiplicative interaction. The
enalapril-ASA interaction term was a significant predictor of at the end of
the study (odds ratio 1.442, p ~ 0.047), and was a borderline-significant pre-
dictor of mortality 30 days after randomization (odds ratio 1.450, p = 0.085).
We used Rothman synergy index S to examine the postulated interaction
with departure from an additive model. S would be equal to unity under ad-
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